AASLD 2016

infohep news

• Hepatitis B

  Is better treatment reducing liver cancer among people with hepatitis B?

  Liz Highleyman / 23 February 2017

  The incidence of hepatocellular carcinoma (HCC) appears to be decreasing and mortality improving among people with chronic hepatitis B treated with suppressive antiviral therapy, according to studies presented at the recent 2016 AASLD ...

• Hepatitis delta

  Lonafarnib lowers hepatitis delta levels with acceptable side-effects

  Liz Highleyman / 27 January 2017

  The hepatitis delta virus (HDV) assembly inhibitor lonafarnib reduces HDV viral load and can be safely boosted with ritonavir to allow for higher and more effective doses with acceptable gastrointestinal ...

• Liver transplants

  Is DAA treatment for hepatitis C reducing the need for liver transplants?

  Liz Highleyman / 25 January 2017

  People successfully treated for hepatitis are less likely to need liver transplants and less likely to die while on a transplant waiting list, according to studies presented at the 2016 ...

• Treatment outcomes

  Curing hepatitis C reduces liver-related complications and death

  Liz Highleyman / 23 January 2017

  People with hepatitis C who achieve sustained virological response to treatment had lower liver-related morbidity and mortality rates compared to people who were not successfully treated, according to research presented at the 2016 ...

• Cirrhosis

  Liver cirrhosis and decompensation still on the rise among people with hepatitis C

  Liz Highleyman / 18 January 2017

  Complications of advanced liver disease including cirrhosis and hepatic decompensation have risen over the past decade among people with chronic hepatitis C, according to study findings presented at the 2016 ...

• Hepatocellular carcinoma (HCC)

  Nivolumab demonstrates good safety and promising response rates in liver cancer study

  Liz Highleyman / 03 January 2017

  Nivolumab (Opdivo), an antibody that blocks the PD-1 receptor and restores T-cell anti-tumour activity, appeared safe and was associated with disease control and stabilisation in a phase 1/2 study of people with hepatocellular ...

• Pan-genotypic regimens

  Glecaprevir/pibrentasvir effective for people with hepatitis C and severe kidney disease

  Liz Highleyman / 22 December 2016

  A two-drug pangenotypic regimen combining AbbVie's glecaprevir and pibrentasvir demonstrated a high sustained response rate for people with chronic hepatitis C who have severe kidney impairment, according to results from the EXPEDITION-4 study ...

• Kidney disease & HCV

  Curing hepatitis C may help reduce kidney disease progression

  Liz Highleyman / 20 December 2016

  People who achieved sustained virological response to interferon-based hepatitis C treatment experienced significantly less decline in kidney function, especially if they had liver cirrhosis, according to study findings presented at the 2016 AASLD ...

• Generic sofosbuvir-based therapy under performs in real-world setting, but is use of suboptimal regimens the reason?

  Michael Carter / 09 December 2016

  Generic sofosbuvir-based combinations may not perform as well as therapy based on branded sofosbuvir-containing regimens, according to result of a study conducted in Qatar and presented to the recent 2016 AASLD Liver Meeting. ...

• New and experimental treatments for hepatitis B

  GS-4774 therapeutic vaccine shows little efficacy in people with hepatitis B

  Liz Highleyman / 08 December 2016

  An experimental immune-based therapy for chronic hepatitis B combined with tenofovir was safe and well tolerated but did not lead to greater reductions in hepatitis B surface antigen (HBsAg) than the antiviral alone, ...